Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3025]

Evaluating the combination of atezolizumab with neoadjuvant chemotherapy for...

Dr Luca Gianni - San Raffaele Hospital, Milan, Italy

Evaluating the combination of atezolizumab with neoadjuvant chemotherapy for the treatment of triple-negative breast cancer ( Dr Luca Gianni - San Raffaele Hospital, Milan, Italy )

Preventative effects of anastrozole in post-menopausal women who are at high...

Prof Jack Cuzick - Queen Mary University of London, London, UK

Preventative effects of anastrozole in post-menopausal women who are at high-risk for developing breast cancer ( Prof Jack Cuzick - Queen Mary University of London, London, UK )

APHINITY: Adding pertuzumab to trastuzumab plus chemotherapy in patients with...

Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium

APHINITY: Adding pertuzumab to trastuzumab plus chemotherapy in patients with operable HER2-positive early breast cancer ( Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium )

Could trastuzumab deruxtecan become the new standard of care for pretreated...

Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA

Could trastuzumab deruxtecan become the new standard of care for pretreated HER2-positive breast cancer patients? ( Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA )

Addition of S-1 to post-operative endocrine therapy for patients with hormone...

Prof Masakazu Toi - Kyoto University, Kyoto, Japan

Addition of S-1 to post-operative endocrine therapy for patients with hormone receptor-positive HER2-negative breast cancer ( Prof Masakazu Toi - Kyoto University, Kyoto, Japan )

Pertuzumab plus trastuzumab and chemotherapy continues to show benefit in HER2...

Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium

Pertuzumab plus trastuzumab and chemotherapy continues to show benefit in HER2-positive breast cancer ( Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium )

Trastuzumab deruxtecan yields promising results in HER2-positive breast cancer...

Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA

Trastuzumab deruxtecan yields promising results in HER2-positive breast cancer patients pretreated with TDM-1 ( Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA )

Myeloma highlights from ASH 2019

Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA

Myeloma highlights from ASH 2019 ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )

Weekly wKRd-D in newly diagnosed multiple myeloma achieves unprecedented results

Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA

Weekly wKRd-D in newly diagnosed multiple myeloma achieves unprecedented results ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )

FLT3-inhibition in infants with acute lymphoblastic leukaemia

Dr Patrick Brown - Johns Hopkins University, Baltimore, USA

FLT3-inhibition in infants with acute lymphoblastic leukaemia ( Dr Patrick Brown - Johns Hopkins University, Baltimore, USA )

Chronic lymphocytic leukaemia highlights from ASH 2019

Dr John Seymour - Peter MacCallum Cancer Centre, Melbourne, Australia

Chronic lymphocytic leukaemia highlights from ASH 2019 ( Dr John Seymour - Peter MacCallum Cancer Centre, Melbourne, Australia )

Benefits of apixaban among venous thromboembolism patients with active cancer

Dr Alexander Cohen - Guys and St Thomas, London, UK

Benefits of apixaban among venous thromboembolism patients with active cancer ( Dr Alexander Cohen - Guys and St Thomas, London, UK )

More from ecancer